創薬流通市場「薬市楽座」
安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。
創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。
なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。
| 掲載日 | シーズ番号 | 作用機序 | 適応症 | 投与経路 | モダリティ | 開発ステージ | 備考 | |
|---|---|---|---|---|---|---|---|---|
| 20/02/18 | GEM156 | Chromatin destabilizing | Solid and hematological tumors | Oral, i.v., i.a | Small molecule | Phase 1 | A First-In-Class chromatin destabilizing agent that intercalates into DNA, and interferes with histone/DNA binding changing its spatial structure. Consequent functional inactivation of a histone chaperon FACT leads to inhibition of several previously undruggable pro-cancer transcriptional factors, activation of p53 and interferon response. Dose-dependent nonclinical antitumor activity is seen in multiple models of solid and hematological tumors. Oral and i.v. phase 1 studies demonstrated a manageable safety profile and disease control with tumor regressions and protracted stable disease. | 問合せ |
| 20/02/18 | GEM155 | FPR2-specific ligand | Atopic dermatitis/ Psoriasis, Dry eye disease, IBD （Inflammatory bowel disease）, Asthma, Rheumatoid arthritis | Topical, Eye drop, s.c. | Peptide | Preclinical | GEM155 is a small (7mer) lipidated peptide ligand for pro-resolving receptor FPR2 (N-formyl peptide receptor 2) involved in regulation of innate immune system and inhibition of ILC2 function (adaptive immune system). It also has anti-microbial effect for pathogenic bacteria through fusion with functional moiety. Efficacy is seen in animal models for the indications. CMC study is almost done. Toxicity study for topical usage and subcutaneous injection is going-on. Formulation for topical use is almost finished. | 問合せ |
| 20/02/18 | GEM154 | Collagen-inducing peptide | Dermal filler, Cosmetics | Topical | Peptide | Preclinical | Laminin-derived peptide. Boosts collagen synthesis at sub-nanomolar concentration (Wrinkle-care) & inhibits melanin synthesis (Whitening). Registered cosmetic ingredient. | 問合せ |
| 20/02/18 | GEM153 | Angiogenic peptide | Wound-care, Diabetic foot ulcer, Cosmetics | Topical | Peptide | Preclinical | Increases blood vessel formation (VEGFA/VEGFR1 expression ↑& cell proliferation/migration ↑). Boosts collagen synthesis at sub-nanomolar concentration (Wrinkle-care) & inhibits melanin synthesis (Whitening). Registered cosmetic ingredient. | 問合せ |
| 20/02/18 | GEM152 | Fat-adsorption inhibitor | Obesity, Diabetes, Fatty liver | Oral | Natural product | Preclinical | Mushroom-derived natural product. Reduces weight gain and obesity, blood glucose and lipid contents in the liver via reduction of lipid absorption in the gut. |
問合せ |
| 20/02/18 | GEM151 | anti-GM-CSF monoclonal antibody | Rheumatoid arthritis & multiple new indications* （see note） | i.v. | Antibody | Preclinical （ready for IND-enabling studies） | GM-CSF is a key player in inflammation and autoimmunity. GEM151 is a fully human monoclonal antibody generated by single B cell cloning and has superior affinity (Kd: 7.3 X 10 -11 M) compared to competitors. Neutralizing activities were confirmed by four different functional assays. *cytokine release syndrome., GvHD, multiple sclerosis/neuroinflammation, Kawasaki disease |
問合せ |
| 20/02/12 | GEM150 | Melanocortin 4 & 5 agonist | Obesity | Oral | Peptide | Preclinical | A pro-drug of the cyclic peptide (BL3020-1) which is a melanocortin 4 & 5 agonist showing good permeability in the gut and BBB and great reduction in food consumption and body weight gain in mice. The pro-drug did not show aggregation which BL3020-1 did. Currently the pro-drug is being optimized. | 問合せ |
| 20/01/29 | GEM149 | PKC modulator | Alzheimer disease | Oral, Intra- nasal | Small molecule | Phase 1 | Up-regulates production of α-secretase which cleaves the amyloid precursor protein, APP, into a harmless soluble form, sAPP-α, which is non-neurotoxic and limits the formation of amyloid plaques. | 問合せ |
| 20/01/29 | GEM148 | CCR5 inhibition | HIV | i.v. | Nucleic acid | Preclinical | GEM148 is a nanoencapsulation of proprietary, synthetic CCR5-siRNA targeted to knock-down and eliminate HIV-1 in chronic HIV patients as well as prevent HIV-1 infection in naïve patients and re-infection in acutely-infected patients. | 問合せ |
| 20/01/29 | GEM147 | Insulin | Diabetes | Oral | Peptide | Preclinical | GEM147 is a nanoencapsulation of insulin in biodegradable polymer nanospheres. Nanoencapsulation protects insulin during stomach passage. In vivo, statistically significant reduction in blood glucose was seen in diabetic rats with oral GEM147 within 30 minutes. | 問合せ |